Logo (1).png
Aureus Greenway Holdings Inc. Announces Pricing of Initial Public Offering and Listing on the Nasdaq Capital Market
February 11, 2025 20:00 ET | Aureus Greenway Holdings Inc.
Kissimmee, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Aureus Greenway Holdings Inc. (the “Company”) (NASDAQ: AGH), an owner and operator of daily fee golf country clubs in the state of Florida, announced...
TilrayBrands_Logo_FullColor_RBG_Horiz-01.png
Tilray élargit son portefeuille de produits à base de cannabis thérapeutique en Allemagne
February 11, 2025 19:02 ET | Tilray Brands, Inc.
NEUMÜNSTER, Allemagne, 12 févr. 2025 (GLOBE NEWSWIRE) -- Tilray Medical, (« Tilray »), une division de Tilray Brands, Inc. (NASDAQ : TLRY et TSX : TLRY) et leader mondial du cannabis...
TilrayBrands_Logo_FullColor_RBG_Horiz-01.png
Tilray erweitert Portfolio an medizinischem Cannabis in Deutschland
February 11, 2025 19:02 ET | Tilray Brands, Inc.
NEUMÜNSTER, Deutschland, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Medical („Tilray“), ein Geschäftsbereich von Tilray Brands Inc. (NASDAQ: TLRY; TSX: TLRY) und ein globaler Marktführer für...
shoals logo.jpg
Shoals Technologies Group Appeals ITC Reversal Decision to Federal Circuit and Receives Institution in New ITC Action Against Voltage
February 11, 2025 18:58 ET | Shoals Technologies Group
Shoals Technologies Group Appeals ITC Reversal Decision to Federal Circuit and Receives Institution in New ITC Action Against Voltage
parazero.png
ParaZero Announces Preliminary Unaudited Results for the Year Ended December 31, 2024
February 11, 2025 18:25 ET | ParaZero Technologies Ltd.
Tel Aviv, Israel, Feb. 11, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "Company or “ParaZero”), an aerospace company focused on safety systems for commercial unmanned...
Microbot Logo.jpg
Microbot Medical Closes $13 Million Registered Direct Offering
February 11, 2025 18:15 ET | Microbot Medical Inc.
BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under...
Anaptys Logo.png
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
February 11, 2025 17:30 ET | AnaptysBio, Inc.
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor...
GOMEKLI™ (mirdametinib) capsules and tablets for oral suspension
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 
February 11, 2025 17:27 ET | SpringWorks Therapeutics, Inc.
– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on positive data from Phase 2b ReNeu trial, which showed GOMEKLI treatment...
axogen logo.jpg
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
February 11, 2025 16:58 ET | Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...
Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
February 11, 2025 16:30 ET | Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...